^
Association details:
| Biomarker: | MPZL3 overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A systemic pan-cancer analysis of MPZL3 as a potential prognostic biomarker and its correlation with immune infiltration and drug sensitivity in breast cancer
Published date:
07/29/2022
Excerpt:
...we analyzed the correlation between MPZL3 expression and drug sensitivity in the top 9 anticancer drugs from the CellMiner database. The results suggested that high MPZL3 expression could decrease the drug IC50 and increase the drug sensitivity of IDH-C227... P-529...and midostaurin...while increasing the drug IC50 and decreasing the drug sensitivity of BAY-876...SR16157...elesclomol...AZD-9496...fulvestrant...and GDC-0077.
DOI:
10.3389/fonc.2022.901728
